Bright Minds Biosciences Inc (DRUG)

Bright Minds Biosciences Inc. is a biotechnology company listed on the NASDAQ under the ticker DRUG. The company focuses on developing therapeutics intended to address severe and life-altering diseases, with an emphasis on neurological and neuropsychiatric conditions. Its pipeline includes work on 5-HT2 receptor-based programs, including serotonin agonists for epilepsy and neuropsychiatric disorders, as well as BMB-101, which has completed a Phase 1 trial for an undisclosed seizure disorder and is now being evaluated in Phase 2 studies for developmental and epileptic encephalopathies and absence epilepsies. Bright Minds Biosciences is also advancing BMB-201 and BMB-202 for neuropsychiatric and neurology indications, along with BMB-105, a 5-HT2C agonist being developed for Prader-Willi syndrome. The company was founded in 2017 and is headquartered in New York, New York.

Jump directly to the stock analysis sections supported by the latest available data.